Long-Term Acceptance of Allografts byin VivoGene Transfer of Regulatable Adenovirus Vector Containing CTLA4IgG andloxP
- 1 March 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 12 (4) , 415-426
- https://doi.org/10.1089/10430340150504037
Abstract
CTLA4IgG was shown to inhibit the costimulatory signal for T cell activation by interfering with the ligation of CD28 and B7-1 or B7-2. To inhibit various immune responses including acute cellular rejection of allografts, a certain level of serum CTLA4IgG should be maintained for an appropriate period. We previously reported on an adenovirus vector containing CTLA4IgG, which we designated Adex1CACTLA4IgG. Adex1CACTLA4IgG was able to maintain a significant level of serum CTLA4IgG for a long period on intravenous injection, which in turn inhibited various immune responses including protective immunity against infectious agents. To overcome the inhibitory effect, we constructed a new adenovirus vector, Adex1CALoxCTLA4IgGLox, by cloning CTLA4IgG cDNA between two loxP sequences under the control of the CAG promoter. We demonstrated that the administration of adenovirus vector containing Cre recombinase gene (Adex1CACre) at the desired time induced Cre-mediated recombination within a gene derived from Adex1CALoxCTLA4IgGLox vector, and the cDNA of CTLA4IgG was excised from the transduced gene and terminated the expression of CTLA4IgG in vitro and in vivo. More importantly, we also demonstrated that the long-term acceptance of allografts was achieved after the termination of CTLA4IgG expression, while the immune response against adenovirus was restored.Keywords
This publication has 32 references indexed in Scilit:
- Persistent and Secondary Adenovirus-Mediated Hepatic Gene Expression Using Adenovirus Vector Containing CTLA4IgGHuman Gene Therapy, 1998
- CTLA4Ig PROLONGS ALLOGRAFT SURVIVAL WHILE SUPPRESSING CELL-MEDIATED IMMUNITYTransplantation, 1994
- Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosisNature Genetics, 1994
- TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-Ig1Transplantation, 1994
- A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7.The Journal of Experimental Medicine, 1993
- Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation MoleculeScience, 1992
- Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lgScience, 1992
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991
- PROLONGATION OF ISLET XENOGRAFT SURVIVAL (RAT TO MOUSE) BY IN VITRO CULTURE AT 37 CTransplantation, 1983
- SKELETAL MUSCLE AS A PRIVILEGED SITE FOR ORTHOTOPIC SKIN ALLOGRAFTSThe Journal of Experimental Medicine, 1973